Mikhail Blagosklonny’s studies focus on aging and cancer. He also lectures at the New York-based Roswell Park Cancer Institute on oncology topics. Blagosklonny is an alumnus of the First Pavlov State Medical University of St Petersburg. He acquired a Ph.D. in cardiology and experimental medicine as well as a master’s degree in internal medicine from the institution.
In 2002, Blagosklonny worked at the New York Medical College as an associate professor. Mikhail Blagosklonny later joined Ordway Research Institute as the senior scientist. As he worked for Ordway Research Institute, he headed the institution’s research strategies. He worked for the institution until 2009 and decided to lecture on oncology at the Roswell Park Cancer Institute. Blagosklonny also researches on molecular and cellular biology topics. He is one of the founders of Cell Cycle, a journal that covers medical topics such as mitosis and cancer cell cycling. Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249451/
Mikhail Blagosklonny is passionate about researching on cancer topics. He majorly focuses on cancer therapies that can protect the human cell from damage. He also researches on biogerontology, which is the study of aging in humans. His primary interest in the field is the production of anti-aging drugs.
He framed a hypothesis on how TOR signaling can be used in aging and cancer. In his hypothesis, Mikhail Blagosklonny also stated that rapamycin could be used to increase the lifespan of cancer patients. Rapamycin is usually used in cancer therapies to reduce the multiplication of cancer cells. According to Blagosklonny, besides reducing the spread of cancer cells, the drug can also boost the immune systems of cancer patients. This research has earned him recognition in longevity studies as an advocate for rapamycin.
Blagosklonny as an Editor
Besides his scientific researches, Blagosklonny works for Oncotarget, Cell Cycle and Aging journals as the senior editor. Oncotarget is an open access journal that covers oncology topics. The journal is usually published by Impact Journals and edited by Mikhail Blagosklonny and Andrei Gudkov. Blagosklonny also works as an associate editor for Cancer Biology and Therapy. He belongs to the editorial board as a member of Cell Death & Differentiation.
Blagosklonny has written more than 270 articles that have been published in several journals. Researchers worldwide have cited his publications more than 25,000 times. He earned an h-index of 83 for his informative publications. He once wrote an article on insulin resistance and diabetic complication that was posted on the PMID journal.
Read works by Mikhail Blagosklonny on Google Scholar